Glenmark Pharmaceuticals Ltd, a global pharmaceutical company, has launched GLIPIQ® (semaglutide) in India, marking a significant step in the affordability of GLP-1 therapy for Type 2 Diabetes Mellitus (T2DM). The weekly treatment cost starts at ₹325, making it a more accessible option for patients.
The introduction of GLIPIQ® aims to reduce the cost barrier that often delays the initiation of advanced injectable therapies. Available in vial and pre-filled pen formulations, the product has been approved by the Central Drugs Standard Control Organization (CDSCO) after a successful Phase III clinical study in India.
The vial-based formulation of GLIPIQ® is designed to offer a flexible and clinically manageable approach to GLP-1 therapy, with dose-specific syringes that cater to patient needs. This format supports physician-guided dosing, particularly in the early stages of treatment, and offers a cost-effective pathway to enhance treatment adherence.
GLIPIQ® vials are priced between ₹325 and ₹440 per week, significantly lowering the cost barrier to GLP-1 therapy in India. The pre-filled pen format provides the convenience of self-dosing for long-term therapy, supporting continuity of care and improved adherence.
Glenmark has also introduced ‘Sankalp’, a patient support programme designed to facilitate therapy initiation and long-term adherence, reflecting the company’s commitment to improving affordability and health outcomes.
Alok Malik, President and Business Head of India Formulations at Glenmark Pharmaceuticals, stated, “With GLIPIQ®, we are setting a new benchmark in affordability for GLP-1 therapy. The vial-based format allows us to offer a more affordable option while supporting clinically guided initiation and flexible dosing.”
Semaglutide, the active component in GLIPIQ®, is a GLP-1 receptor agonist used in managing Type 2 Diabetes, particularly in patients with comorbidities such as obesity, cardiovascular disease, and chronic kidney disease.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).